Abstract. The present study aimed to evaluate whether the neoadjuvant chemoradiation response with concurrent thermal therapy for the treatment of rectal cancer can be predicted following the first thermic treatment. Eighty patients with primary rectal adenocarcinoma (≤12 cm from the anal verge) were included in this study. Fifty-four received surgery and pathological response was evaluated. Intensity-modulated radiotherapy was administered conventionally once daily 5 times/week. Neoadjuvant radiotherapy consisted of 50 Gy delivered to the planning target volume in 25 fractions. Concurrent neoadjuvant chemotherapy was delivered in 5-day courses. Capecitabine was administered orally at 1,700 mg/m 2 /day for 5 days/week. Thermic treatment was performed using the Thermotron-RF 8 and administered once/week for 5 weeks with 50 min irradiation. Patients with a gross tumor volume (GTV) ≤32 cm 3 and a radiofrequency (RF) output difference (RO difference) ≥77 Watt/min exhibited pathological complete response (pCR) and CR rates of 50 and 75%, respectively. Those with a GTV ≥80 cm 3 and a RO difference ≥77 Watt/min exhibited pCR and CR rates of 42.9 and 42.9%, respectively. The changes in the skin temperature during RF treatment in patients with pCR with a RO difference ≥77 Watt/min increased significantly compared with those of other outcomes, and progressive disease. These data suggest a strategy for predicting which patients will respond best following the first thermic treatment. The results identified that the group of patients with a GTV ≤32 cm 3 and a RO difference ≥77 Watt/min (outputable/heatable patients) may respond best.
Introduction
Neoadjuvant management philosophy depends on the ability to predict the extent of pathological response using clinical, imaging, and molecular parameters (1) (2) (3) . Thus far, no parameters have been validated in multi-institutional prospective trials or used prior to starting treatment. New pretreatment or posttreatment clinical, imaging, and molecular data are required to monitor and predict treatment outcomes in radiotherapy.
Neoadjuvant chemoradiation (NACR) for the treatment of rectal cancer significantly increases the rate of pathological complete response (pCR). Moreover, the local recurrence rate is significantly lower among patients who received neoadjuvant radiation, while there is no significant difference with respect to disease-free survival or overall survival (4) (5) (6) (7) (8) .
In contrast, there has been also reported that NACR reduces the rate of local recurrence and improves local control, which appears to result in improved overall survival (9) (10) (11) (12) (13) (14) . Moreover, a certain subset of patients may not require surgery at all according to the 'wait-and-see' paradigm (15) . On the basis of these favorable results, NACR has been accepted as the standard therapy worldwide except in Japan.
Meanwhile, radiofrequency (RF) hyperthermia using the Thermotron-RF 8 has been administered mainly in Japan but incurs a risk of the 'hotspot' phenomenon, a potentially fatal complication induced by RF treatment itself. To resolve this problem, we established thermal therapy with standardized power escalation principles, i.e., 'neothermia,' and devised a predictive formula for output-limiting symptoms (16, 17) The present study aimed to evaluate whether NACR response with concurrent thermal therapy for the treatment of rectal cancer can be predicted after the first thermic treatment. Because early assessment of treatment efficacy, and the decision on continuation or cessation of cancer therapy are necessary for the good quality life of the cancer patients.
Materials and methods
Between December 2011 and May 2015, 80 consecutive patients with primary rectal adenocarcinoma localized in the rectum (up to 12 cm from the anal verge) were included. All patients received pre-and post-treatment diagnostic examinations including CT, PET/CT, and MRI at Hidaka Hospital. The extent and location of the tumors were classified according to the tumor-node-metastasis staging (18) . We classified the location of the tumor by the results of MRI, CT and colonoscopy.
All patients received NACR with concurrent thermal therapy at Hidaka Hospital. Operations were performed at the Department of General Surgical Science, Gunma University, or the Division of Surgery, Hidaka Hospital. Each resected specimen was evaluated histologically at the Department of Pathology, Gunma University. This study was approved by the ethics committees of Hidaka Hospital and Gunma University. Each patient gave written informed consent. Tumor stages were defined on the basis of colonoscopy, barium enema, CT, or 18 . At present we think that it is difficult to evaluate patients that would assure a statistically powerful and unequivocal result. So we use the quartiles method to classify tumors into 4 groups and finally found the correlation among GTV ≤32, 33-79, and ≥80 cm 3 and RO difference RO difference: ≤76 Watt/min and RO difference: ≥77 Watt/min in this study.
Chemoradiotherapy. The GTV was contoured using the Focal Treatment Planning system (Focal, Eindhoven, The Netherlands), taking into consideration clinical information from imaging modalities to identify the primary rectal tumor and enlarged regional lymph nodes. The CTV included the GTV plus a 15-mm margin in the anterior, posterior, and lateral directions and a 25-mm margin in the craniocaudal direction in addition to the entire mesorectum and internal iliac and presacral nodes. The cranial border was S2/3 interspace in order to reduce the irradiated small bowel volume. On the basis of our institutional setup data, the PTV was determined by adding a 3-mm margin around the CTV.
IMRT was administered conventionally, once daily, 5 times/week using TomoTherapy ® (Hi-Art ® treatment system; ACCURAY ® , Inc., Sunnyvale, CA, USA) and neoadjuvant radiotherapy of 50 Gy delivered to the PTV in 25 fractions. The small intestines, bladder, and bilateral femur were contoured and defined as organs at risk (OAR). The doses to OARs were limited as follows: V98 <45 Gy for PTV, V15 <52.5 Gy for PTV, and V10 <55 Gy for PTV. Capecitabine (Cap) was administered orally at a dose of 1,700 mg/m 2 /day, 5 days per week during the first to fifth weeks of NACR, beginning the day of the start of radiation therapy and ending with the last dose of radiation therapy.
Thermal therapy. Thermic treatment was administered using the Thermotron-RF 8 (Yamamoto Vinita Co., Ltd., Osaka, Japan) once per week for 5 weeks with 50 min irradiation. Precise methods of thermal therapy were described elsewhere (16, 17, 19, 20) .
A sensor catheter with four temperature points was attached to the skin on the lateral abdomen of 68 patients. The average surface skin temperature of the four temperature points during each irradiation was measured to calculate the average surface skin temperature of the five thermal treatments.
Evaluation of treatment response and adverse effect.
Objective response was evaluated from week 2-18, with a median of 8 weeks, and the timing of surgical resection ranged from weeks 9-43, with a median of 16 weeks after the completion of NACR with concurrent thermal therapy. Response was evaluated according to the response evaluation criteria in solid tumors using MRI, CT, or PET/CT (21) . CR was defined as total disappearance of the lesions and partial response (PR) was defined as a 30% decrease in the sum of the diameters of the lesions until the period of the evaluation. Stable disease (SD) was defined as between a 30% decrease and 20% increase in the sum of the diameters of the lesions. Finally, Progressive disease (PD) was defined as a 20% increase in the sum of diameters of the lesions or new distant metastasis. We evaluated CR as the disappearance of the tumor on PET/CT and MRI as well as a positive-to-negative change on PET/CT.
Resected specimens were graded according to the Japanese Classification of Colorectal Carcinoma as follows: Pathological grade 0, no fibrosis in the specimen; grade 1a, denaturation and necrosis of cancer cells in approximately <1/3 of the cancer; grade 1b, denaturation and necrosis in <2/3 of cancer cells plus fusion in >1/3 of the cancer; grade 2, significant denaturation, necrosis, fusion, and loss in >2/3 of the cancer; grade 3 (i.e., pCR), no cancer cells observed in both primary and regional lymph nodes (18) . Adverse effects were evaluated on the basis of the Common Terminology Criteria for Adverse Events (4.0) (22) .
Statistical analysis. SPSS v21 (IBM Corp., Armonk, NY, USA) was used for all statistical analyses. Mean values were compared using paired Student's t-test and ANOVA with Tukey-Kramer HSD (honestly significant difference) test for multiple comparisons. Categorical data were analyzed using the χ 2 test. All reported P-values are two-tailed and P<0.05 was considered to indicate a statistically significant difference..
In the present study, by using the predictive formula for output-limiting symptoms mentioned above, we used an initial time of 0 min for the time at which an output limiting symptom occurred as a predicted initial RF output (IRO (Watt)), and compared it to the actual observed RF output (i.e. RO difference (Watt/min)=average actual observed RO (Watt/min) during 50 mins RF irradiation-predicted IRO). For RO differences, the Table I . Characteristics of 80 patients according to the RO differences. quartiles were ≤-153, -152 to -77, -76 to 76, and ≥77 Watt/min at the first thermal treatment.
Results

Patients' characteristics.
Among the 80 patients, 26 (32.5%), 32 (40%), 9 (11.3%), and 13 (16.3%) achieved CR, PR, SD, and PD, respectively. Consequently, 11 (13.8%), 20 (25%), 18 (22.5%), 5 (6.3%), 12 (15%), and 14 (17.5%) patients were pCR (i.e., grade 3), grade 2, grade 1-0, CR, PR-SD in no resection, and PD included 4 resections, respectively. Reduced tumor burdens were observed in 37/53 (69.8%) patients. In the therapeutic response, there was no significant difference between macroscopic types such as polypoid or ulcerative tumors. Because polypoid tumors were small number. Table I shows patients' characteristics according to the RO differences. There were significant differences in body mass index and internal organs fat area between patients with the RO difference ≤76 Watt/min and ≥77 Watt/min.
Treatment response according to the GTVs. Fig. 1 shows the results of treatment response according to the GTVs (≤32 cm 3 , 33-79 cm 3 , and ≥80 cm 3 ) among 80 patients (A) and RECIST criteria (B). The highest CR and pCR were shown 85.0 and 30%, respectively, in patients with a GTV ≤32 cm 3 . There were significant differences in treatment responses among GTVs in (A) and (B) (χ 2 =30.423, P=0.001 and χ 2 =34.385, P<0.0001, respectively).
Treatment response according to the RO differences. Fig. 2 shows the results of treatment response according to the RO differences (≤-153 Watt/min, -152-76 Watt/min, and ≥77 Watt/min among 80 patients (A) and RECIST criteria (B). The highest CR and pCR were shown 38.1 and 23.8%, respectively, in patients with a RO difference ≥77 Watt/min. There was no significant difference in treatment responses among RO differences in (A) and (B) .
Treatment response of according to the RO difference.
Figs. 3 and 4 shows the results of treatment response of RECIST criteria (Fig. 3 ) and 80 patients (Fig. 4) ). The highest rates of CR (87.5%) were observed in patients with a GTV ≤32 cm 3 and a RO difference ≤76 Watt/min (Fig. 3) , while a RO difference ≥77 Watt/min group showed higher rates of pCR in those with a GTV ≤32 cm 3 or ≥80 cm 3 (50.0% or 42.9%, respectively) than the RO difference ≤76 Watt/min group (Fig. 4) . There was a significant difference in treatment responses among GTVs in RECIST criteria patients with a RO difference ≤76 Watt/min group (Fig. 3A) (χ 2 =34.526, P<0.0001) and not in those with a RO difference ≥77 Watt/min group (Fig. 3B) . There was also a significant difference in treatment responses among GTVs in 80 patients with a RO difference ≤76 Watt/min group (Fig. 4A) (χ 2 =24.365, P=0.007) and not in those with a RO difference ≥77 Watt/min group (Fig. 4B) .
Changes of the surface skin temperature. Changes of the surface skin temperature during the 50 min of irradiation are shown in Fig. 5 . Skin temperature significantly changed in patients with a pathological grade 3 tumor compared both to those who had PD and other outcomes, only in the RO difference ≥77 Watt/min group (Tukey-Kramer HSD test, P<0.001). In the RO difference ≤76 Watt/min group there was no significant difference among patients with grade 3, other outcomes and PD.
Toxicity. NACR with concurrent thermal therapy was tolerated well, with 96.3% of patients receiving the full dose of chemotherapy and 100% receiving the full dose of radiotherapy with 5 sessions of thermal therapy. Grade 3 toxicity was observed in 7/80 (8.8%) patients. Six of them were classified as non-hematologic toxicity. The remaining one patient had hematologic toxicity as anemia. There was no significant difference between hematologic and non-hematologic toxicity. During thermic treatment, 72 (90%) patients experienced at least one instance of a troublesome hotspot phenomenon such as pain/irritable sensations (85%) and subcutaneous induration (6.3%).
Discussion
The positive outcome of IMRT plus Cap has been demonstrated by pCR rates ranging from 14.1-30.6%, with grade 3 toxicity rates from 11.1-17.6% (6, 8, (23) (24) (25) (26) (27) . These results suggest IMRT has the potential for higher tumor control rates and/or less toxicity for patients. Nevertheless, more accurate and precise delineation of the target is required. Recentry, Valentini et al (28) recommended PTV used is 10-15 mm in view of rectal motion.
In trials of preoperative helical tomotherapy for rectal cancer, De Ridder et al (29) reported that the metabolic response rate was 45% in the non-boosted group compared with 77% in the boosted group. Huang et al (30) reported that there was no significant differences between patients who received tomotherapy or other therapy with respect to pCR (14.3% vs. 8.8%), T downstaging (60% vs. 61.4%), N downstaging in patients with cN1-2 (69.6% vs. 79.1%), ypT0-2N0 (57.1% vs. 43.9%), or sphincter preservation rate for low-lying rectal cancer (85.2% vs. 80.0%). Four patients in the tomotherapy group (11.1%) and 10 in the other therapy group (16.7%) developed G3 acute toxicities during CRT.
From the viewpoint of hyperthermia, Maluta et al (31) reported that hyperthermia plus chemoradiation resulted in 23.6% patients achieving pCR and 5.2% patients with PD. Schroeder et al (32) retrospectively compared neoadjuvant radiation with concurrent 5-FU-based chemotherapy with and without hyperthermia in 106 rectal cancer patients; pCR was achieved by 6.7 and 16.4% of patients, respectively. The rate of sphincter-sparing surgery was 57% in the hyperthermal radiochemotherapy group compared with 35% in the radiochemotherapy group.
Among the nonrandomized and randomized studies mentioned above, none describe the associations of outcomes among dosimetric parameters such as physical volumes of TVs of tumors or the associations between physical volumes of TVs and patient outcomes.
Although our idea based on the results of NACR with concurrent thermal therapy is novel, one possible explanation is that both radiation and RF treatment have electromagnetic effects owing to low-energy, low-frequency (8 MHz) waves and high-energy, high-frequency (>3x10 19 Hz) waves on cancer cells, respectively. This results in concurrent RF treatment appearing to have a potential filter effect on the results of radiation treatment, because outputable/heatable conditions may be associated with good response to chemoradiation (20) .
The present study has some limitations. First, the small sample size meant there was no comparison group that received radiotherapy with concurrent Cap. Second, the post-treatment follow-up duration was short. Therefore, further studies should be performed to confirm these results.
The results show that the associations between parameters of TVs, patients' state and change of body temperature are good predictors of outcomes in patients with rectal cancer who receive NACR with concurrent thermal therapy. First, GTV ≤32 cm 3 patients are indicated for this NACR with or without concurrent thermic treatment and second, large tumor patients (GTV ≥80 cm 3 ) need to treat this NACR with concurrent thermic treatment. And also our idea might be able to use for early assessment of treatment efficacy, and will help the decision of the continuation or cessation of this treatment modality.
